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Abstract
Purpose Notch signaling was recently found to be associ-
atedwithprognosisofsomecancers.Theaimofthestudyisto
investigate signiﬁcance of the expression of HES1/HES5
protein, downstream effectors of Notch, in prognosis of the
patients with advanced ovarian epithelial cancers.
Methods Formalin-ﬁxed, parafﬁn embedded tissues and
clinic-pathological parameters from 61 patients with FIGO
stage IIIc–IV ovarian serous adenocarcinoma were collected,
the expression of HES1 and HES5 protein were immunohis-
tochemicallydetected,andtheassociationofHES1andHES5
expression with survival of the patients were analyzed.
Results The expressions of both HES1 and HES5 in
adenocarcinoma were signiﬁcantly higher than those in
adenoma and normal control (v
2 = 32.915, P = 0.000 and
v
2 = 46.863, P = 0.000 respectively). Overall survival
and disease-free period were longer in HES1 low-expres-
sion patients (median 43.0 and 22.0 months) than those in
high-expression patients (median 24.0 and 14.5 months).
Of those, Overall survival period of patients with HES1
low-expression was signiﬁcantly longer than that of those
with high-expression (v
2 = 4.049, P = 0.044). Univariate
analysis and multivariate Cox regression model did not
show that HES1 or HES5 expression was a factor associ-
ated with survival of advanced ovarian serous adenocar-
cinoma patients.
Conclusions The expressions of bHLH gene HES1 and
HES5 are increased in advanced ovarian serous adenocar-
cinomas, and HES1 high-expression probably is a potential
poor prognostic factor for the patients.
Keywords Ovarian serous cancer   bHLH gene  
HES gene   Prognosis
Background
Epithelial ovarian cancer is the leading cause of death from
gynecologic cancers, accounting for 5% of all cancer
deaths. Despite of efforts aiming at improving methods of
early diagnosis, the majority of cases of ovarian cancer are
not diagnosed until the disease has spread throughout
whole peritoneal cavity. Since Munnell introduced a con-
cept of the ‘‘maximum surgical effort’’ for ovarian cancer
in 1968, cytoreductive surgery as the primary management
of ovarian cancer has been widely performed in the world.
Meanwhile, a series of novel chemotherapeutic agents and
combination drug regimens have been identiﬁed to be
clinically active. Primary cytoreductive surgery followed
by platinum-based combination chemotherapy has been
recognized as a standard strategy of management for
ovarian cancer. However, there appears to be little change
in ovarian cancer mortality in past several decades, and
ﬁve-year survival rates of those with advanced disease
have been still remaining under 30% (Hoskins et al. 2000).
It is well known that many factors affect ovarian can-
cer prognosis, such as the age of patient, tumor stage,
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preoperative CA-125 level, amount of ascites, and others.
Surgery alone is rarely, if ever, curative for patients with
advanced ovarian cancer, even in those without gross
residual disease after successful cytoreduction. It is nec-
essary for all of the advanced ovarian cancer patients to
undergo chemotherapy. Thus, the response to chemother-
apy should be the most important factor associated with
prognosis of ovarian cancer patients. Various kinds of
mechanisms are involved in resistance to chemotherapy,
including pharmacokinetics, tumor microenvironment and
intrinsic factors in tumor cells. Of those, the latter is a key
factor that inﬂuences the response to chemotherapy. It has
been veriﬁed that many signal molecules controlling cel-
lular proliferation, division, differentiation and death par-
ticipate in resistance to chemotherapeutic drugs in cancer
cells, for instance, microtubule-interfering agent (e.g.
EM012), protein kinase (e.g. PI3K/Akt), epithelial growth
factor receptor, and others (Zhou et al. 2005; Mozzetti et al.
2005; Lee et al. 2005; Park et al. 2005; Fu et al. 2007).
Recently, it was found that survival signaling by Notch
participated in not only carcinogenesis but also chemo-
resistance in some malignancies (Nefedova et al. 2004;
Mungamuri et al. 2006). However, the role of basic-helix-
loop-helix transcription factors (bHLH genes) including
HES genes, as downstream molecules and effectors of
Notch, in regulating the response to chemotherapy for
cancer is rarely reported and still poorly understood up to
date, though it has been revealed that the expression of
HES protein is associated with the prognosis of patient
with cervical cancer (Liu et al. 2007), mucoepidermoid
carcinoma (Behboudi et al. 2006), and others.
Ovarian serous tumor is the most common histological
subtype arising from the surface epithelium of the ovary,
and accounts for nearly half of ovarian epithelial tumors, of
those, about one-third are malignancies. In the study, we
collected the formalin-ﬁxed, parafﬁn embedded tissues and
clinic-pathological parameters from 61 patients with stage
IIIc–IV ovarian serous adenocarcinoma, immunohisto-
chemically detected the expressions of HES1 and HES5
protein, and analyzed their associations with survival of the
patients. The aim of the study was to investigate signiﬁ-
cance of HES1/HES5 protein expression in prognosis of
the patients with advanced ovarian epithelial cancers.
Materials and methods
Specimen and patient
All specimens were obtained from the Pathological
Department of Women’s Hospital, School of Medicine,
Zhejiang University from January 1999 to December 2004.
During this period, the Gynecologic Department of the
Hospital adopted 461 ovarian cancer patients. In 461
patients, 104 underwent primary cytoreductive surgery in
our Department, diagnosed as FIGO stage IIIc–IV diseases,
and histologically conﬁrmed as serous adenocarcinoma. Of
those, 61 received total six-course platinum-based combi-
nation chemotherapy following surgery in our Department
and had completely clinic-pathological data. Thus, those 61
patients were ﬁnally enrolled into the study. Meanwhile,
tissues from 20 normal ovaries and 47 ovarian serous
adenomas were collected as controls in our study. Normal
ovarian tissues were collected from perimenopausal
women with myoma who underwent adnexectomy and
hysterectomy. The informed consent on collection of
samples was obtained by each patient. The study was
approved by the Medical Ethics Committee of Women’s
Hospital, School of Medicine, Zhejiang University
according to the guidelines of in compliance with the
Helsinki Declaration.
In 61 ovarian serous adenocarcinoma patients (24–
74 years, median 49 years) undergoing primary cytore-
duction, 28 patients had equal to or less than 2 cm of
residual tumor and 33 patients more than 2 cm; 55 patients
were FIGO stage IIIc and 6 patients stage IV; 5 patients
were pathological grade 1(G1), 19 patients G2, and 37
patients G3 according to WHO grading system. All of the
patients underwent platinum-based combination chemo-
therapy for six courses following primary surgery.
Chemotherapy regimens included PC (cisplatin/carboplatin
and cyclophosphamide) in 25 patients, PAC (cisplatin/
carboplatin, adriamycin, and cyclophosphamide) in 11, TP
(paclitaxel and cisplatin) in 12, and TC (paclitaxel and
carboplatin) in 13. The interval of chemotherapy was 28
days and the dose of drug was calculated according to the
body surface area or AUC such as carboplatin.
Chemotherapy response was evaluated after six courses
of chemotherapy for each patient. The evaluation of che-
motherapy response was according to objective response or
CA125 response criteria. Objective response was assessed
with the WHO criteria (Miller et al. 1981) and CA125
response was evaluated according to the criteria proposed
by Bridgewater et al. (1999). Complete and partial remis-
sion were regarded as effective and remained ones as non-
effective.
All of the patients were followed up by interview in
clinic or phone call. The total period of follow-up was
12–108 months.
Clinic-pathologic parameter collection
The clinic-pathologic parameters associated with prognosis
of the patients were collected, including the age of patients,
pathological grade, size of residual tumor, ascites amount,
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123pre-operative maximum tumor diameter, preoperative
serum CA125 level, and response to primary chemotherapy.
Immunohistochemistry and evaluation
The rabbit anti-human polyclonal antibodies speciﬁc for
HES1 and HES5, respectively, were purchased from
United States Biological (Swampscott, MA, USA).
All tissues were immediately ﬁxed in 10% neutralized
formalin for 24 h prior to processing to parafﬁn wax using
standard procedures. Parafﬁn sections (4 lm) were used for
histologic diagnosis or immunohistochemistry. Tissue
sections were dewaxed and rehydrated using standard
procedures. Hydrated autoclave pretreatment was in
10 mM citrate buffer (pH 6.0) boiling for 2 min. Endogen
peroxidase activity was blocked with 3% hydrogen per-
oxidase for 10 min at room temperature (RT). Slides were
incubated with polyclonal rabbit antibodies diluted 1:400
(HES1) and 1:100 (HES5) in Tris-buffered solution
(50 mM Tris–HCl, 150 mM NaCl, pH 7.4) at RT for 1 h;
then incubated with Dako Envision
TM Peroxidase (Dako
Diagnostica, Hamburg, Germany) for 30 min at RT. For
visualization of the antigen, 3,30-diaminobenzidine tetra-
hydrochloride (Dako) was added at RT. Slides were
washed 3 9 5 min in phosphate buffered saline (PBS)-
Tween between each step. Then the slides were counter-
stained with Mayer’s hematoxylin, rinsed in tap water,
dehydrated, placed in xylene, and mounted. Blank controls
were performed by replacing primary antibodies with
normal rabbit serum (Dingguo, Beijing, China). Positive
cell was indicated by the presence of distinct brown in the
nuclear or cytoplasm of cells. The number of positively
stained cells out of 100 in ten random ﬁelds (4009
objective) was counted and represented as the percentage
of positive cells. The semiquantitative immunoreactive
score was ranged from - (0) to ??? (3) based on the
percentage of positive cells and the stain intensity. The
percentage of positive cells was scored as follows, - (0)
means less than 5% positive cells; ? (1) 5–25% positive
cells; ?? (2) 26–75% positive cells; and ??? (3) more
than 76% positive cells. The staining intensity was also
scored on a four-tiered scale (negative 0, low intensity
positive staining 1, moderate intensity positive staining 2,
and strong intensity positive staining 3). The staining
intensity score adding the positive cell score is the overall
score. Slides, as well as IHC scorings, were independently
reviewed by two empirical pathologists (two of authors)
without the knowledge of clinical data.
In order to perform a sensitive statistical analysis,
all cases were divided into two groups according to HES1/
HES5 expression. Signiﬁcant statistical association with
prognosis was observed using a cut-off of four in the
overall score of HES1/HES5 expression. Patients with
overall score B4 were called low-expression, while
patients with overall score[4 were called high-expression
(Innocenzi et al. 2003).
Statistics
Chi-square test was performed using SPSS 16.0 software
package for Windows. Multivariate Cox regression model
was performed to identify independent risk factors asso-
ciated with patient survival. A level of 0.05 was chosen to
indicate statistical signiﬁcance. All reported P values were
bilateral.
Results
HES1 and HES5 expressions in ovarian serous
adenocarcinoma
HES1 and HES5 immunostaining were located in cellular
nucleus or cytoplasm. Both HES1 and HES5 were mod-
erately or strongly expressed in ovarian serous carcinoma,
in contrast to weakly or not expressed in adenoma and
normal ovarian tissues. Typical HES1 and HES5 immu-
nostaining in normal, serous adenoma, and carcinoma were
shown in Fig. 1.
There were signiﬁcant differences of HES1 and HES5
expression among normal, adenoma, and carcinoma groups
(v
2 = 32.915, P = 0.000 and v
2 = 46.863, P = 0.000
respectively). Expressions of HES1 and HES5 in carcinoma
were signiﬁcantly higher than those in adenoma and normal
control, but not different between adenoma and normal
(Table 1). The expression between HES1 and HES5 was
signiﬁcantly correlated in ovarian serous adenocarcinoma
(r = 0.284, P = 0.027).
The associations of HES1 and HES5 expression
with the response to chemotherapy for stage IIIc–IV
ovarian serous adenocarcinoma
In 61 patients, 40 were effective and 21 non-effective to
chemotherapy. There were no signiﬁcant associations of
HES1 and HES5 expression with chemotherapy response
(Table 2).
The associations of HES1 and HES5 expression
with the prognosis of ovarian serous adenocarcinoma
patients
All 61 patients were followed up for 12–108 months, of
those, 11 patients were lost. In remained 50 patients, 39
patients relapsed and seven underwent second operation,
11 did not relapse till end of follow-up. Median overall and
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Fig. 1 Expressions and
localizations of HES1 and
HES5 protein in normal ovarian
tissue, adenoma and
adenocarcinoma. The distinct
brown staining was located in
the nuclear or cytoplasm of
positive cells
Table 1 Expressions of HES1 and HES5 in different ovarian tissues
Total N = 128 HES1 HES5
Low-expression
N = 98
High-expression
N = 30
P
 Low-expression
N = 96
High-expression
N = 32
P

Adenocarcinoma 61 33 28 29 32
Adenoma 47 45 2 0.000* 47 0 0.000
§
Normal 20 20 0 0.000** 20 0 0.000
§§
 P value among three groups in HES1, v
2 = 32.915, P = 0.000
 P value among three groups in HES5, v
2 = 46.863, P = 0.000
* Adenomas versus adenocarcinoma, v
2 = 22.95
** Normal versus adenocarcinoma, v
2 = 14.030
§ Adenomas versus adenocarcinoma, v
2 = 35.037
§§ Normal versus adenocarcinoma, v
2 = 17.344
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123disease-free survival period for the patients with HES1
low-expressions were 43.0 and 22.0 months, while those
with high-expressions were only 24.0 and 14.5 months
respectively. Overall survival period in patients with HES1
low-expression was signiﬁcantly longer than that in those
with high-expression (v
2 = 4.049, P = 0.044), but no
differences of overall and disease-free survival periods
were found between patients with HES5 low-expression
and high-expression, as shown in Fig. 2 and 3. Both uni-
variate analysis and multivariate Cox regression model did
not show that HES1 or HES5 expression was a factor
associated with survival of advanced ovarian serous ade-
nocarcinoma patients, as shown in Tables 3 and 4.
Discussion
Mammary cell fate and cell differentiation are governed by
a variety of signaling pathways in which Notch signaling
cascade plays a key role. In many settings, cell fate deci-
sion occurs through ligand–receptor interactions that utilize
Notch signaling cascade. Receptor activation by a Notch
ligand can lead to the speciﬁc fate of a cell, while failure of
activation leads to a different fate (Politi et al. 2004).
Helix-loop-helix (bHLH) genes are important targets in
mammalian Notch pathway. HES gene, homolog of
Drosophila hairy and enhancer of split, is one member of
the bHLH superfamily of DNA binding transcription fac-
tors and expressed in a wide variety of cells, particularly in
epithelial and neuro-epithelial cells of the developing
embryo (Axelson 2004). There are seven subtypes in the
HES gene, including HES1 throughout HES7. Among
seven members, HES1 and HES5 are essential effectors of
Notch signaling, the expression of which is up regulated by
Notch activation. As mediators of Notch signaling, HES1
and HES5 normally have a key role in the process of
embryogenesis or in neural stem cells (Axelson 2004; Shi
et al. 2008). Mis-expressions of HES1 and HES5 inhibit
neuronal differentiation and maintain neural stem cells in
the embryonic brain, in contrast, neural progenitors
undergo premature neuronal differentiation in HES1 and
HES5 double knockout mice (Shi et al. 2008). In addition
to CNS, recent studies have revealed that HES1 and HES5
also participate in the regulation of differentiation in other
tissue and cell types, such as blood cells, endocrine–
exocrine cells, somites, adipocytes, muscles, and so on
(Miyazaki et al. 2005; Ross et al. 2006). HES genes are
Table 2 The associations of Hes1 and Hes5 expression with the response to chemotherapy for stage IIIc–IV ovarian serous adenocarcinoma
Total N = 61 HES1 HES5
Low-expression High-expression v
2 P Low-expression High-expression v
2 P
Chemo-response 0.038 0.845 1.146 0.284
Non-effective 21 11 10 8 13
Effective 40 22 18 21 19
Fig. 2 Overall and disease-free survivals of the patients with HES1
low-expression and high-expression. Overall survival period of
patients with HES1 low-expression was signiﬁcantly longer than that
of those with high-expression (v
2 = 4.049, P = 0.044)
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123thought to prevent cellular differentiation and maintain the
population of undifferentiated precursor cells (Jensen et al.
2000). Thus, the function of HES genes implies that they
may involve in the occurrence and development of tumors.
Recent studies have shown mis-expressions of HES1 and
HES5 in human malignancies such as lung cancer, chol-
angiocarcinoma, murine leukemia, and others (Ishimura
et al. 2005; Ito et al. 2000), but some of the results
appeared to oppose to their function in physiologic con-
dition. For instance, activation of HES1 expression induced
the differentiation of neuroblastoma cells, the process of
which was probably inhibited by Notch1 (Axelson 2004),
induction of HES1 led to suppression of proliferation in
carcinoid tumor cells (Kunnimalaiyaan et al. 2005) and
HES1 could inhibit 17b-estradiol-induced cell proliferation
in breast cancer (Stro ¨m et al. 2000). However, the recent
studies also revealed opposite results. Hopfer and
colleagues reported that HES1 protein was strongly
expressed in 18/19 ovarian epithelial carcinoma samples
(Hopfer et al. 2005). Kimura et al. (2007) recently showed
via establishing pancreatic cancer in mice that Notch1 and
HES1 were immunohistologically expressed in lesions
ranging from tubular complexes to carcinoma in tHESe
chemically induced pancreatic tumors. Disagreed results
regarding HES effect on tumorigenesis reported by dif-
ferent authors may be due to different cancer cell types. A
recent study of ours showed that not only HES1 and HES5
expression were signiﬁcantly higher in cervical carcinoma
compared with cervical intraepithelial neoplasia and nor-
mal cervical epithelium, but also over-expressions of HES1
and HES5 were positively correlated with some poor
Fig. 3 Overall and disease-free survivals of the patients with HES5
low-expression and high-expression. No differences of overall or
disease-free survival between HES5 low-expression and high-expres-
sion were found
Table 3 Univariate analysis on the associations of HES1/HES5
expression and clinic-pathological parameters with 5-year survival
rate
Clinic-pathological
parameter
No. 5-year
survival
rate (%)
v
2 P value
Age (year)
B50 32 21.9 0.015 0.901
[50 18 27.9
Pathological grade
G1 4 0.0 0.918 0.764
G2 15 26.7
G3 31 22.6
Maximum tumor diameter (cm)
B10 36 22.2 0.011 0.918
[10 14 28.6
Ascites amount (ml)
B500 27 29.6 1.020 0.313
[500 23 17.4
Size of residual tumor (cm)
B2 22 40.9 6.158 0.013
[2 28 10.7
Serum CA125 (u/ml)
B1,000 27 29.6 1.020 0.313
[1,000 23 17.4
HES1
Low-expression 25 32.0 1.754 0.185
High-expression 25 16.0
HES5
Low-expression 22 18.2 0.729 0.393
High-expression 28 28.6
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123prognostic factors in early stage cervical carcinoma,
including later stage, lymph node metastasis, poor differ-
entiation, larger tumor size ([2 cm), and deeper cervical
invasion (Liu et al. 2007). In this study, we found that the
expressions of HES1 and HES5 were signiﬁcantly higher in
ovarian serous adenocarcinoma than those in adenoma and
normal control, suggesting that increased expressions of
HES1 and HES5 protein exist in ovarian serous cancer and
probably contribute to tumor progression and poorer prog-
nosis. The elevated HES1 and HES5 expression were proba-
blyinducedbyNotchactivation,but a further studyisneeded
for exploring which Notch paralog is responsible for such
induction because one Notch paralog may play different role
from other in Hes activation (Beatus et al. 1999).
The association of Notch signaling with response to
chemotherapy and prognosis in cancer patients has been
relatively well clariﬁed. Nefedova and colleagues found
that activation of Notch-1 resulted in protection of mye-
loma and malignant lymphoid cells from melphalan- and
mitoxantrone-induced apoptosis and this protection was
associated with up-regulation of p21 (WAF/Cip) and
growth inhibition of cells (Nefedova et al. 2004). Similarly,
Notch1 protein participated in P53-mediated chemoresis-
tance in breast cancers (Colaluca et al. 2008). A clinical
study showed that activating Notch1 mutations could pre-
dict favorable early chemotherapy response and long-term
outcome in childhood precursor T-cell lymphoblastic leu-
kemia (Breit et al. 2006). However, the inﬂuence of HES
genes, essential effectors of Notch signaling, on response to
chemotherapeutic drugs was still very rare reported up to
date. A recent study in vitro and in mice model by
Nefedova and colleagues showed that inhibition of Notch
signaling prevented drug resistance and sensitizes mye-
loma to chemotherapy, and HES1 mediated this procedure
(Nefedova et al. 2008). Although we did not ﬁnd that the
patients with different Hes expressions presented different
responses to chemotherapy in this study, our clinical fol-
low-up data showed that overall and disease-free survival
period of the patients with HES1 low-expression were
longer than those with high-expression, especially a sig-
niﬁcant difference of overall survival existed between
HES1 low-expression and high-expression. This is the ﬁrst
primary clinical investigation on the correlation between
HES protein expression and prognosis in ovarian epithelial
cancers, to our knowledge. Our ﬁndings suggest that the
expressions of bHLH gene HES1 and HES5 are increased
in advanced ovarian serous adenocarcinomas, and HES1
high-expression probably is a potential poor prognostic
factor for the patients. However, our univariate analysis
and multivariate Cox regression model did not show that
HES1 or HES5 expression was a factor associated with
survival of advanced ovarian serous adenocarcinoma
patients. It is likely to be due to lack of enough samples and
a further study with more cases seems to be needed.
In conclusion, our results suggest that the expressions of
bHLH gene HES1 and HES5 are increased in advanced
ovarian serous adenocarcinomas, and HES1 high-expres-
sion probably is a potential poor prognostic factor for the
patients.
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